US FDA panel to take on knotty anti-NGF challenge
This article was originally published in Scrip
The US FDA has been grappling with the knotty challenge of how to regulate an experimental class of drugs, known as anti-nerve growth factors (anti-NGFs), which regulators said "represent a potentially significant and novel strategy for the treatment of pain," but have been linked to osteonecrosis and avascular necrosis (AVN) – all leading to joint replacement – and wants a panel of outside experts to help the agency decide whether to permit drug makers to proceed with clinical testing.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.